Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Sell
36
BNTX Quote, Financials, Valuation and Earnings
Last price:
$99.52
Seasonality move
:
34.37%
Day range:
$97.94 - $99.70
52-week range:
$76.53 - $131.49
Dividend yield:
0%
P/E ratio:
191.55x
P/S ratio:
8.03x
P/B ratio:
1.18x
Volume:
685.1K
Avg. volume:
844.1K
1-year change:
7.06%
Market cap:
$23.9B
Revenue:
$3B
EPS (TTM):
-$3.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
$154.7M | -$2.68 | -10.55% | -56.56% | $139.99 |
|
GSK
GSK PLC
|
$10.1B | $1.05 | 2.57% | 57.14% | $43.42 |
|
MRNA
Moderna
|
$121.2M | -$3.08 | -19.37% | -0.05% | $54.40 |
|
NVAX
Novavax
|
$150.3M | $0.14 | -27.87% | -50.48% | $16.43 |
|
PFE
Pfizer
|
$13.5B | $0.57 | -3.03% | 29.69% | $31.32 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
$99.47 | $139.99 | $23.9B | 191.55x | $0.00 | 0% | 8.03x |
|
GSK
GSK PLC
|
$39.49 | $43.42 | $80.5B | 24.94x | $0.40 | 3.94% | 2.04x |
|
MRNA
Moderna
|
$34.62 | $54.40 | $13.4B | -- | $0.00 | 0% | 4.20x |
|
NVAX
Novavax
|
$7.99 | $16.43 | $1.3B | -- | $0.00 | 0% | 1.83x |
|
PFE
Pfizer
|
$25.72 | $31.32 | $145.8B | 18.24x | $0.43 | 6.57% | 2.30x |
|
TCBP
TC BioPharm (Holdings) PLC
|
$1.73 | -- | $887.5K | -- | $0.25 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BNTX
BioNTech SE
|
1.29% | 1.349 | 0.97% | 7.26x |
|
GSK
GSK PLC
|
53.74% | 0.176 | 29.19% | 0.49x |
|
MRNA
Moderna
|
-- | 0.488 | -- | 3.45x |
|
NVAX
Novavax
|
-37.36% | 9.314 | 13.16% | 0.89x |
|
PFE
Pfizer
|
41.92% | 0.618 | 43.87% | 0.82x |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.548 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
$1B | $924.4M | -3.35% | -3.39% | 25.13% | -$605.5M |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
MRNA
Moderna
|
$217M | -$1.2B | -29.09% | -29.09% | -123.22% | $303M |
|
NVAX
Novavax
|
$51.6M | -$131.1M | -- | -- | -74.73% | -$175.4M |
|
PFE
Pfizer
|
$11.9B | $3.2B | 5.09% | 8.91% | 4.1% | $5.8B |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
BioNTech SE vs. Competitors
-
Which has Higher Returns BNTX or GSK?
GSK PLC has a net margin of 21.81% compared to BioNTech SE's net margin of 5.1%. BioNTech SE's return on equity of -3.39% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE79.54% $1.15 $20.5B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About BNTX or GSK?
BioNTech SE has a consensus price target of $139.99, signalling upside risk potential of 40.73%. On the other hand GSK PLC has an analysts' consensus of $43.42 which suggests that it could grow by 9.96%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE13 5 0 GSKGSK PLC2 3 1 -
Is BNTX or GSK More Risky?
BioNTech SE has a beta of 0.302, which suggesting that the stock is 69.756% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.601, suggesting its less volatile than the S&P 500 by 39.914%.
-
Which is a Better Dividend Stock BNTX or GSK?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GSK PLC offers a yield of 3.94% to investors and pays a quarterly dividend of $0.40 per share. BioNTech SE pays -- of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BNTX or GSK?
BioNTech SE quarterly revenues are $1.3B, which are smaller than GSK PLC quarterly revenues of $10.4B. BioNTech SE's net income of $276.6M is lower than GSK PLC's net income of $530.1M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while GSK PLC's PE ratio is 24.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.03x versus 2.04x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.03x 191.55x $1.3B $276.6M GSKGSK PLC2.04x 24.94x $10.4B $530.1M
-
Which has Higher Returns BNTX or MRNA?
Moderna has a net margin of 21.81% compared to BioNTech SE's net margin of -117.16%. BioNTech SE's return on equity of -3.39% beat Moderna's return on equity of -29.09%.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE79.54% $1.15 $20.5B MRNAModerna22.7% -$2.91 $10.9B -
What do Analysts Say About BNTX or MRNA?
BioNTech SE has a consensus price target of $139.99, signalling upside risk potential of 40.73%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE13 5 0 MRNAModerna5 17 1 -
Is BNTX or MRNA More Risky?
BioNTech SE has a beta of 0.302, which suggesting that the stock is 69.756% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.
-
Which is a Better Dividend Stock BNTX or MRNA?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or MRNA?
BioNTech SE quarterly revenues are $1.3B, which are larger than Moderna quarterly revenues of $956M. BioNTech SE's net income of $276.6M is higher than Moderna's net income of -$1.1B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.03x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.03x 191.55x $1.3B $276.6M MRNAModerna4.20x -- $956M -$1.1B
-
Which has Higher Returns BNTX or NVAX?
Novavax has a net margin of 21.81% compared to BioNTech SE's net margin of -91.76%. BioNTech SE's return on equity of -3.39% beat Novavax's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE79.54% $1.15 $20.5B NVAXNovavax58.48% -$0.51 -$454.2M -
What do Analysts Say About BNTX or NVAX?
BioNTech SE has a consensus price target of $139.99, signalling upside risk potential of 40.73%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 105.61%. Given that Novavax has higher upside potential than BioNTech SE, analysts believe Novavax is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE13 5 0 NVAXNovavax3 2 0 -
Is BNTX or NVAX More Risky?
BioNTech SE has a beta of 0.302, which suggesting that the stock is 69.756% less volatile than S&P 500. In comparison Novavax has a beta of 2.916, suggesting its more volatile than the S&P 500 by 191.569%.
-
Which is a Better Dividend Stock BNTX or NVAX?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or NVAX?
BioNTech SE quarterly revenues are $1.3B, which are larger than Novavax quarterly revenues of $88.3M. BioNTech SE's net income of $276.6M is higher than Novavax's net income of -$81M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.03x versus 1.83x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.03x 191.55x $1.3B $276.6M NVAXNovavax1.83x -- $88.3M -$81M
-
Which has Higher Returns BNTX or PFE?
Pfizer has a net margin of 21.81% compared to BioNTech SE's net margin of 2.31%. BioNTech SE's return on equity of -3.39% beat Pfizer's return on equity of 8.91%.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE79.54% $1.15 $20.5B PFEPfizer66.74% $0.07 $152.1B -
What do Analysts Say About BNTX or PFE?
BioNTech SE has a consensus price target of $139.99, signalling upside risk potential of 40.73%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that BioNTech SE has higher upside potential than Pfizer, analysts believe BioNTech SE is more attractive than Pfizer.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE13 5 0 PFEPfizer6 13 1 -
Is BNTX or PFE More Risky?
BioNTech SE has a beta of 0.302, which suggesting that the stock is 69.756% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.
-
Which is a Better Dividend Stock BNTX or PFE?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. BioNTech SE pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or PFE?
BioNTech SE quarterly revenues are $1.3B, which are smaller than Pfizer quarterly revenues of $17.8B. BioNTech SE's net income of $276.6M is lower than Pfizer's net income of $410M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.03x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.03x 191.55x $1.3B $276.6M PFEPfizer2.30x 18.24x $17.8B $410M
-
Which has Higher Returns BNTX or TCBP?
TC BioPharm (Holdings) PLC has a net margin of 21.81% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -3.39% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE79.54% $1.15 $20.5B TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About BNTX or TCBP?
BioNTech SE has a consensus price target of $139.99, signalling upside risk potential of 40.73%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2674.57%. Given that TC BioPharm (Holdings) PLC has higher upside potential than BioNTech SE, analysts believe TC BioPharm (Holdings) PLC is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE13 5 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is BNTX or TCBP More Risky?
BioNTech SE has a beta of 0.302, which suggesting that the stock is 69.756% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BNTX or TCBP?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. BioNTech SE pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or TCBP?
BioNTech SE quarterly revenues are $1.3B, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. BioNTech SE's net income of $276.6M is higher than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.03x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.03x 191.55x $1.3B $276.6M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
